Department

The Beijing University Hospital for Oncology Phase I Clinical Disease Center was established in 2014, and is one of the first clinical centers in the country to focus on promoting early development of innovative anti-tumor drugs.The center is committed to rapidly advancing clinical research and development of innovative anti-tumor drugs, with a focus on clinical research and development.The Phase I Clinical Disease Center has 15 conventional beds, five regular clinical units per week. The family room has a strong technical expertise, managed more than 200 early clinical trials, received more than 10,000 referrals from patients across the country, and promoted the approval of several innovative anti-tumor drugs such as Vidicotyl, Envoli, and Sugli. New types of anti-tumor therapies, such as cell therapy, micro-nucleic acid drugs, and the leukavirus, with extensive clinical trial experience, are nationally ranked at the top. Furthermore, the specialist care teams in this area have GCP qualifications and basic emergency skills to provide complete safety for patients. The main faculty includes: 2 physicians as director, 2 doctors as associate director, 1 associate researcher, 4 physicians as head, 1 doctoral student, 1 master's student.